Managing Editor, Diabetes in Control, Author at Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals.

SGLT-2 Inhibitors’ Association with Fournier Gangrene

Dec 10, 2019 Paid, SGLT-2 Therapy Center 2,677 views

While rare, Fournier gangrene infections can worsen rapidly and have serious consequences.

Resistant Hypertension Predicts Mortality Outcomes in T2D

Dec 7, 2019 Cardiology, Type 2 Diabetes 2,173 views

Resistant hypertension and type 2 diabetes lead to both microvascular and macrovascular complications.

Can Breastfeeding Keep Mom’s Heart Healthy?

Dec 7, 2019 Paid, Women's Health 2,457 views

Breast milk is deemed to be the “best” for baby, but what are the additional benefits for mothers and their long-term health?

Cardiovascular and Renal Benefits of SGLT2 Inhibitors

Dec 3, 2019 Cardiology, Nephrology, SGLT-2 Therapy Center 9,692 views

The use of SGLT-2 inhibitors produces cardiovascular benefits and reduces the risk of progression of renal impairment in patients with T2DM.

Lower Treatment Rates of Depression For Some Type 2 Patients

Dec 3, 2019 Mental Health 2,253 views

Does being a member of a minority ethnicity put you at risk of being overlooked for depression?

Little Known Benefit in Using SGLT2 Inhibitors

Dec 3, 2019 Paid, SGLT-2 Therapy Center 3,584 views

While the major impact of hypomagnesemia on cardiovascular outcomes and T2DM has been known, recent evidence suggests that SGLT2 inhibitors may normalize Mg2+ levels.

Antineoplastic Activity of Metformin

Nov 30, 2019 Metformin Therapy Center, Paid 5,675 views

Conflicting findings on metformin’s possible relationship to cancer.

Why Add A GLP-1 Agonist To Existing Treatment for Type 2 Diabetes?

Nov 30, 2019 GLP-1 Agonist Therapy Center, Type 2 Diabetes 4,244 views

Adding Dulaglutide, Liraglutide or Semaglutide (GLP-1 agonists) to existing treatment for type 2 diabetes has major cardiovascular benefits. Exenatide* and Lixisenatide were neutral for providing cardiovascular benefits.